Morning Overview on MSN

Scientists identified a new form of brain-cell death behind Alzheimer’s and dementia

Researchers at Oregon Health and Science University have identified ferroptosis, an iron-driven form of cell death, in ...

Riftbound Vendetta card reveal - Helm of Suppression stops ramps dead, and ruins late-game spellcasting

While we're excited to reveal Riftbound Vendetta's Helm of Suppression, we're sorry in advance for all of the chaos it's ...
TMCnet

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical ...

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone. Entered into a clinical trial collaboration and supply agreement with Bayer ...

First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients

Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat ...

Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets

Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and ...
TMCnet

TheWell Bioscience Launches RocketCell™ Cell Viability Enhancer to Improve Cell Recovery, Survival, and Expansion Following Passaging, Cryopreservation, and Organoid Harvesting

Proprietary small-molecule formulation extends beyond conventional ROCK inhibitors to accelerate recovery and improve reproducibility in stem cell and organoid research. MONMOUTH JUNCTION, N.J., July ...

SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, ...
The University of Alabama at Birmingham

UAB trial shows first-in-human immunotherapy that more than doubles progression-free survival in glioblastoma patients

UAB researchers report Phase 1 trial results showing a novel immunotherapy safely doubled the time glioblastoma patients ...
The Manila Times

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That ...

SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering C ...

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That ...

SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...
Healio

Subcutaneous amivantamab induces durable responses in metastatic head, neck cancer

Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head ...